Health Canada issued a Notice of Compliance with Conditions for Eisai/Biogen’s lecanemab (LEQEMBI) for adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are ApoE ε4 non‑carriers or heterozygotes and have confirmed amyloid pathology. The decision makes LEQEMBI the first disease‑modifying anti‑amyloid therapy authorized for early AD in Canada. Eisai and Biogen framed the approval as evidence the antibody reduces amyloid protofibrils and plaques and slows clinical decline; the companies said they will work with stakeholders to support timely patient access. LEQEMBI is already authorized in multiple jurisdictions and remains subject to post‑approval safety monitoring. The conditional approval underscores regulatory willingness to permit treatments that demonstrate disease‑modifying effects for early Alzheimer’s while continuing confirmatory evaluation.